An Open-Label, Positron Emission Tomography (PET) Study to Evaluate the Brain 5 HT6 Receptor Occupancy by Single Doses of SLV354 in Healthy Male Subjects and Subjects With Stable Schizophrenia.
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2012
At a glance
- Drugs SLV 354 (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Mar 2012 New trial record